<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052931</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-KIL-GC-006</org_study_id>
    <nct_id>NCT05052931</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer</brief_title>
  <official_title>Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer, a Small-scale, Exploratory Real-world Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jianjun Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, open, historically controlled real-world study.&#xD;
&#xD;
      The aims of this study is to evaluate the safety and effectiveness of Nab-paclitaxel combined&#xD;
      with oxaliplatin and S-1 in the treatment of patients with advanced gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE</measure>
    <time_frame>2-year</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by NCI-CTCAE V5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>7-month</time_frame>
    <description>ORR is defined as the rate of complete response (CR) or partial response (PR), as determined by IRC using RECIST v1.1 criteria among patients with at least one target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>7-month</time_frame>
    <description>The proportion of all subjects who assessed the best overall curative effect as CR, PR, and disease stable (SD) according to the RECIST 1.1 standard.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2-year</time_frame>
    <description>It is defined as the time from the first doses durg to the time of death due to any reason.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel combined with oxaliplatin and S-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel combined with oxaliplatin and S-1</intervention_name>
    <description>Nab-paclitaxel 100mg/m^2, D1, Q3W; oxaliplatin 85 mg/m^2, D1, Q3W; S-1 60 mg/m^2, D1-14, Q3W; Neoadjuvant chemotherapy 2 cycles, followed by surgery, continue to receive 6 cycles of adjuvant chemotherapy.</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gastric adenocarcinoma diagnosed by histology.&#xD;
&#xD;
          -  Ambulatory cases, 18-75 years old&#xD;
&#xD;
          -  ECOG performance status ≤ 1&#xD;
&#xD;
          -  Have not received anti-tumor therapy previously (such as surgery, radiotherapy,&#xD;
             chemotherapy, targeted therapy, immunotherapy)&#xD;
&#xD;
          -  Patients able to tolerate abdominal surgery above grade 3&#xD;
&#xD;
          -  Has adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  WBC&gt; 4.0×10^9/L&#xD;
&#xD;
               -  ANC&gt; 1.5×10^9/L&#xD;
&#xD;
               -  ANC ≥ 1.5×10^9/L&#xD;
&#xD;
               -  HB ≥ 80 g/L&#xD;
&#xD;
               -  PLT ≥ 100×10^9/L&#xD;
&#xD;
               -  TBIL ≤ 1.5×ULN&#xD;
&#xD;
               -  ALT and AST &lt;2.5 × ULN, for patients with liver metastases, ALT and AST &lt;5 × ULN&#xD;
&#xD;
               -  BUN and Cr ≤ 1.5 × ULN or endogenous creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  No history of other tumors&#xD;
&#xD;
          -  Be willing and able to comply with the plan during the research period&#xD;
&#xD;
          -  Has given written informed consent&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those with a history of other malignancies in the last 5 years, except for cured&#xD;
             non-melanoma skin cancer and cervical carcinoma in situ&#xD;
&#xD;
          -  HER-2+ and willing to receive Trastuzumab&#xD;
&#xD;
          -  Pregnancy or breast-feeding women; Men and women who are sexually active (possible to&#xD;
             have children) and unwilling to use contraception during the study period&#xD;
&#xD;
          -  Severe, uncontrolled medical diseases and infections; chronic bowel disease or short&#xD;
             bowel syndrome&#xD;
&#xD;
          -  Major organ failure, such as compensatory cardiopulmonary liver and kidney failure;&#xD;
             severe liver and kidney metabolism abnormalities, affecting the normal metabolism of&#xD;
             drugs&#xD;
&#xD;
          -  Patients with other surgical contraindications, such as serious diseases that are&#xD;
             difficult to control&#xD;
&#xD;
          -  The researcher believes that patients with a clear gastrointestinal bleeding tendency&#xD;
             and/or patients with abnormal blood coagulation function (INR &gt; 1.5)&#xD;
&#xD;
          -  Active HBV or HCV&#xD;
&#xD;
          -  Peripheral neuropathy ≥ Grade 2 according to NCT-CTC AE5.0&#xD;
&#xD;
          -  Patients who are allergic to the drugs in this study, or determined by the&#xD;
             investigator as unsuitable to participate in this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of the Air Force Medical University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianjun Yang</last_name>
      <phone>029-84771532</phone>
      <email>yangjj@fmmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>Jianjun Yang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

